How We Got Here: A Field Guide to the Fentanyl Crisis in Canada and on Hamilton's Streets
How We Got Here: A Field Guide to the Fentanyl Crisis in Canada and on Hamilton's Streets
Introduction
What you are seeing on the streets of downtown Hamilton in 2026 — the open wounds, the forward-leaning catatonia, the people who appear neither awake nor unconscious but suspended in some grotesque middle state — is not the same drug crisis Canada has been talking about for the last decade. It is the visible end product of a thirty-year cascade that began in a pharmaceutical boardroom in Connecticut, accelerated when North American regulators tried to clamp down on prescription opioids without addressing demand, was industrialized by Chinese chemical exporters and Mexican synthesizers, and has now mutated, in 2023–2026, into a polysubstance "tranq dope" supply that is pharmacologically distinct from the heroin or even the early-fentanyl street drug of five years ago. Layered on top of that are a national housing collapse, the closure of Ontario's supervised consumption sites, and a stimulant (methamphetamine) co-use pattern that produces the gaunt, agitated, sleep-deprived appearance many Hamiltonians have started calling "zombie-like."
This report walks through that arc — historical, supply-side, pharmacological, clinical, and political — distinguishing what is well-established from what is contested, and tying it back to what the user is observing in Hamilton.
1. Historical Roots: Purdue, OxyContin, and the Pivot to Fentanyl
The Canadian OxyContin story
OxyContin — Purdue Pharma's controlled-release oxycodone — was approved by Health Canada in 1996, the same year as in the United States. A 2022 retrospective analysis by Pappin, Bavli, and Herder of the actual Health Canada submission found that none of Purdue's clinical trials meaningfully assessed addiction or misuse, the longest trial ran only 24 days, and the resulting product monograph contained the now-infamous claim that "drug abuse is not a problem in patients with pain in whom oxycodone is appropriately indicated." No maximum dose was specified, and the monograph instructed clinicians to increase the dose if 12-hour pain relief failed — language that aligned almost perfectly with Purdue's later sales pitch.
Purdue Pharma Canada then ran an aggressive marketing campaign that mirrored the U.S. strategy: distributing a Purdue-funded pain-management book free to medical students at the University of Toronto from 2004 to 2010, sponsoring continuing medical education, and pushing the drug well beyond cancer pain. Crucially, when the U.S. FDA added a Black Box warning and revised the OxyContin label in 2001, Health Canada did not follow suit until 2006 — a roughly five-year gap during which Purdue was legally entitled to use the original, misleading Canadian monograph in promotional materials. Bavli's 2020 paper in Addiction concludes that this regulatory delay was a material contributor to the Canadian over-prescription epidemic. Unlike in the United States, where Purdue and three executives paid $634.5 million in 2007 for misbranding, Purdue Pharma Canada has never admitted wrongdoing and was never criminally prosecuted; a 2017 class-action settled for only CA$20 million, and the federal government declined to bring charges under the Food and Drugs Act.
By the late 2000s, oxycodone was the top-selling long-acting opioid in Canada, and Canada had become — and remains — the world's second-highest per-capita prescriber of opioids after the United States.
2012: The reformulation, delisting, and the supply shock
In February 2012, Purdue replaced OxyContin with OxyNeo, a tamper-resistant formulation that could not be crushed or dissolved for injection. Within weeks, in March 2012, seven Canadian provinces delisted OxyContin from their public drug formularies. Between 2012 and 2016, total milligram-equivalents of opioids dispensed in Canada fell about 15%, with much sharper drops in BC (-30%) and Ontario (-23%).
This is the textbook example of a supply-side intervention producing classic substitution effects. People with established opioid use disorder did not stop using — they switched. Vancouver cohort data from Karamouzian and colleagues showed self-reported regular use of unregulated opioids rising as OxyContin became unavailable. Initially, that meant heroin and diverted hydromorphone. But because Canada's heroin supply was relatively thin (compared to the U.S.) and traffickers had a powerful new economic option, the substitute that quickly came to dominate was illicit fentanyl.
Why fentanyl made economic sense for traffickers
Fentanyl is roughly 50–100 times more potent than morphine and 30–50 times more potent than heroin by weight. That potency-to-weight ratio collapses the entire smuggling economics. A kilogram of heroin requires acres of irrigated poppy, processing labs, and bulky transcontinental shipping. A kilogram of fentanyl can be produced in a single garage from chemicals shipped in a small parcel, and it yields the equivalent of 25–50 kilograms of heroin in street effect. The DEA has estimated each fentanyl pill costs about $1 to produce and resells for $10–30. Once Mexican and Chinese networks figured this out around 2013–2014, the heroin market in North America was, in effect, doomed.
Fentanyl's arrival in the Canadian street supply
The published surveillance trail is consistent. Fentanyl was first reported in BC and Alberta around 2011. The BC Coroners Service detected it in 4% of illicit drug deaths in 2012; that share rose to 15% in 2013, 25% in 2014, 29% in 2015, 67% in 2016, and 82–87% from 2017 onward, where it has plateaued. BC's Provincial Health Officer declared a public health emergency in April 2016. Alberta followed a similar curve, while Ontario's fentanyl wave hit two to three years later — public-health officials and the chief coroner have repeatedly described how fentanyl "made its way east from British Columbia" in 2015–2016. By 2024, fentanyl and its analogues were involved in 83% of Ontario opioid toxicity deaths.
Policy decisions that shaped the curve
Several distinctly Canadian policy choices mattered. Provincial formulary delistings in 2012 created the supply shock. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain, led by McMaster University's Jason Busse, sharply tightened prescribing. Health Canada restricted opioid marketing in 2018. BC pioneered a take-home naloxone program (now over 400,000 kits annually) that has clearly saved lives. Insite, North America's first sanctioned supervised injection site, opened in Vancouver in 2003; the federal Conservative government tried to close it but was rebuffed by the Supreme Court in 2011. From 2020 onward, BC and other jurisdictions experimented with "safer supply" — physician-prescribed pharmaceutical hydromorphone as an alternative to the toxic illicit market — a policy that has since become deeply contested (see Section 6).
2. The Supply Chain: Where Canadian Fentanyl Actually Comes From
This is the most politically charged part of the story, so it requires careful separation of established fact, plausible inference, and contested speculation.
China as the precursor source
The well-established facts: From roughly 2013 to 2019, China was the dominant direct source of finished fentanyl shipped via international mail to North American consumers, and remains the dominant source of precursor chemicals — most importantly NPP (N-phenethyl-4-piperidone), 4-ANPP (4-anilino-N-phenethyl-4-piperidine), and a rotating cast of pre-precursors. Brookings' Vanda Felbab-Brown, the U.S.-China Economic and Security Review Commission, the DEA's National Drug Threat Assessments, and the U.S. Congressional-Executive Commission on China all converge on this.
Under U.S. pressure, China class-scheduled all fentanyl analogues effective May 1, 2019. The result was real but limited: shipments of finished fentanyl from China to North America fell sharply, but Chinese chemical companies pivoted to selling precursors and pre-precursors (chemicals one step further back in the synthesis pathway, which were not yet scheduled). The DEA's 2024 National Drug Threat Assessment is explicit that the Sinaloa and Jalisco (CJNG) cartels now do most of the synthesis, using Chinese precursors arriving at Mexican Pacific ports — primarily Manzanillo and Lázaro Cárdenas — with finished fentanyl trafficked north into the U.S. India has emerged as a secondary precursor source since 2018, and DEA documents specific cases in which production shifted from China to India after the 2017–2019 Chinese scheduling actions.
The contested-but-credible territory: A bipartisan 2024 report by the U.S. House Select Committee on the CCP, building on years of investigative work, alleged that the Chinese government provides VAT export rebates that effectively subsidize the export of precursors used to make fentanyl, holds ownership stakes in some of the chemical companies involved, and selectively censors domestic but not export-facing fentanyl-related online content. These claims are based on document analysis and web-scraping of Chinese e-commerce sites and have not been substantively rebutted, though Chinese authorities deny them. Whether this constitutes deliberate "weaponization" or simply the predictable behaviour of a mercantilist regulatory system that prioritizes export revenue is a legitimate analytical dispute.
The Canada-supply question: domestic production vs. cross-border flows
Canada's fentanyl situation is structurally different from the United States'. Two well-documented patterns coexist:
(a) Domestic "superlab" production in Western Canada. The October 2024 RCMP raid in Falkland, BC — about 50 km east of Kamloops — uncovered what the RCMP called the largest and most sophisticated drug superlab ever found in Canada. Seizures included 54 kg of finished fentanyl, 390 kg of methamphetamine, 89 firearms, and precursor chemicals capable of producing roughly 95 million potentially lethal fentanyl doses. The RCMP linked the operation to a transnational organized-crime group. Canadian Foreign Affairs has acknowledged in policy documents that "seizures of Canada-sourced fentanyl in places like the U.S. and Australia suggest that domestic production is likely exceeding domestic demand," meaning Canada is now a source country for some markets, particularly Australia and New Zealand where street prices are several times higher than in North America. The RCMP says it has dismantled 44 clandestine labs since 2018.
(b) The cross-border trade with the United States is genuinely small. This is where the Trump-administration narrative collapses on contact with the data. In U.S. fiscal year 2024, of approximately 21,900 pounds of fentanyl seized at U.S. borders, roughly 43 pounds — about 0.2% — were seized at the northern border; the rest were seized at the southwest border, overwhelmingly from U.S.-citizen drivers passing through legal ports of entry. CBP data tracked by the Manhattan Institute (Caulkins and Giri, July 2025) found that U.S. counties on the Mexican border, with 2.35% of the U.S. population, accounted for 40% of large fentanyl seizures, while counties on the Canadian border (3.1% of population) accounted for 1.2% of powder and 0.5% of pill seizures. The DEA's 2024 NDTA does not contain the word "Canada." Brookings' Vanda Felbab-Brown, Carnegie Mellon's Jonathan Caulkins, and the bipartisan Commission on Combating Synthetic Opioid Trafficking all concur that Canada is "not a major source" of U.S.-bound fentanyl.
The politically inconvenient nuance: northern-border seizures did rise in 2024–2025, from less than 1 kilogram in FY 2023–24 to about 19.5 kilograms in FY 2024–25 — an 1,800-plus percent increase that is real in percentage terms but trivial in absolute terms, and that Canada's "fentanyl czar" Kevin Brosseau has acknowledged warrants attention. The Trump tariffs imposed in 2025 used these percentage figures to justify treating Canada and Mexico as comparable threats, which the underlying weight data does not support.
The "weaponization" / foreign-interference question
This is genuinely contested terrain and worth handling carefully.
The substantiated findings: The Cullen Commission of Inquiry into Money Laundering in BC (final report 2022) concluded that organized crime had laundered billions of dollars through BC casinos and real estate, with significant ties to Chinese transnational networks — the "Vancouver Model" first described by Australian academic John Langdale. The U.S. Treasury's October 2023 OFAC sanctions against Vancouver-based Bahman Djebelibak and his Health Canada–licensed company Valerian Labs, for their role in a China-based network trafficking fentanyl, methamphetamine, and MDMA precursors, are well-documented. Canada's own intelligence community (CSIS, RCMP Federal Policing) acknowledges Triad/CCP nexus concerns at a high level.
The Hogue Commission (Public Inquiry into Foreign Interference in Federal Electoral Processes), final report January 28, 2025, focused primarily on election interference, not fentanyl. Its conclusion was that foreign interference is real and serious but that there is "no evidence of 'traitors'" in Parliament. It did not adjudicate the broader fentanyl-as-state-attack thesis.
Sam Cooper's reporting (Wilful Blindness, 2021; The Bureau substack) is the most prominent journalistic synthesis of the "deliberate hybrid warfare" framing. Cooper has done genuine investigative work that has been corroborated by U.S. officials, Cullen Commission evidence, and OFAC sanctions. He has also been the subject of credible criticism: Global News settled a defamation lawsuit by Liberal MP Han Dong in 2025 after the Hogue Commission found classified intelligence corroborated Dong's denial of Cooper's central claim, and other reporters and national-security commentators have criticized specific stories for inadequate sourcing. The honest summary is: Cooper's structural thesis — that Chinese state actors tolerate and benefit from precursor exports, that Triad money-laundering through Vancouver is a serious problem, and that Canada has been institutionally slow to act — is broadly supported by other evidence. Specific allegations naming individuals have been shakier and have lost in court. Treat his framing as a useful but partisan lens, not as established consensus.
What credible academic and law-enforcement sources do not support is the strongest version of the claim: that the fentanyl crisis is primarily a deliberate, top-down PRC campaign to kill North Americans the way the British East India Company pushed opium into China. The closer-to-consensus view, articulated by Felbab-Brown and others, is that the PRC's permissiveness is opportunistic and revenue-driven rather than a coordinated act of war, but that the practical effect — mass North American death — is the same regardless of intent.
Adjudicating the recent Falkland-DEA dispute
In late 2025, The Bureau published interviews with retired DEA Acting Administrator Derek Maltz alleging that the RCMP refused to coordinate with the DEA on the Falkland investigation despite DEA having developed the original intelligence. If accurate, this is a serious institutional failure rather than evidence of malice; senior U.S. officials have repeatedly cited this kind of stovepiping as a reason for tariff pressure. Canadian officials dispute the framing.
3. Pharmacology: Why Fentanyl Is Different
Why fentanyl is so much more potent
Fentanyl, like morphine and heroin, is a full agonist at the mu-opioid receptor (MOR), a G-protein-coupled receptor that, when activated, suppresses pain signaling, produces euphoria, and — most dangerously — depresses brainstem respiratory drive. What makes fentanyl unusual is not particularly higher MOR binding affinity (its Ki of ~1.35 nM is similar to morphine's ~1.17 nM in recombinant human MORs). The potency advantage instead comes from its physicochemistry.
Fentanyl is roughly 600 times more lipophilic than morphine. Recent molecular-dynamics work (Kelly et al., British Journal of Pharmacology, 2023; bioRxiv preprints 2021–2025) suggests fentanyl partitions directly into the lipid bilayer of cell membranes and may approach the receptor through the transmembrane helices rather than via the extracellular aqueous route used by morphine. This produces a "drug depot" effect: fentanyl accumulates in membranes near the receptor at concentrations far higher than in surrounding fluid, which explains both its 50–100x in vivo potency advantage and the increasingly documented clinical phenomenon that fentanyl overdoses often require multiple doses of naloxone to reverse, with reversal sometimes followed by re-overdose ("re-narcotization") as fentanyl redistributes out of fat into blood.
Carfentanil — used legitimately only to anesthetize elephants — is roughly 100 times more potent than fentanyl and 10,000 times more potent than morphine. It has appeared sporadically in the BC supply since 2016 and was implicated in 126 BC deaths in 2022 alone.
The narrow therapeutic window
In a pharmaceutical setting, a fentanyl patch delivers a precise microgram-per-hour dose. On the street, the entire problem is that the active dose (a few hundred micrograms) and the fatal dose (1–3 milligrams in an opioid-naive person, much higher in someone tolerant) are separated by only about a factor of ten, and street fentanyl is mixed by hand or in pill presses with no quality control. A "hot spot" in a poorly-mixed batch — a single grain extra — can be the difference between getting high and dying. Because tolerance to opioid-induced respiratory depression develops more slowly than tolerance to euphoria, even regular users push themselves toward overdose chasing the same high.
How dependence develops
Repeated MOR activation triggers receptor downregulation, desensitization (uncoupling of MOR from G-proteins), and compensatory upregulation of the cAMP system in locus coeruleus neurons. The result is twofold: tolerance (more drug needed to produce the same effect) and physical dependence (a withdrawal syndrome — sweating, vomiting, diarrhea, severe muscle and bone aches, autonomic instability, profound dysphoria — when the drug is removed). With short-acting agents like fentanyl, withdrawal can begin within 4–8 hours of the last dose and is sufficiently miserable that even highly motivated patients without medication-assisted treatment relapse at very high rates. This neuroadaptive trap is why opioid agonist therapy with methadone or buprenorphine produces dramatically better outcomes than abstinence-based approaches.
The current adulteration crisis: benzodope and tranq
This is what makes the 2024–2026 street drug pharmacologically distinct from the 2015–2020 fentanyl era.
Benzodiazepine adulteration ("benzodope"). Since 2018, Canadian drug-checking services have detected non-medical benzodiazepines — most notably etizolam, flualprazolam, and now overwhelmingly bromazolam — mixed into fentanyl. Health Canada's Drug Analysis Service in 2021 found benzodiazepines in 60.7% of opioid samples. UVic's Substance project in March 2024 found bromazolam in 50.5% of expected-opioid samples checked, with concentrations sometimes equivalent to two 2 mg Xanax bars per "point" (100 mg). Ontario's Office of the Chief Coroner reports that non-prescription benzodiazepines were detected in 62% of opioid toxicity deaths in 2024. Bromazolam, like all benzodiazepines, does not respond to naloxone — naloxone reverses the opioid component, restoring breathing, but the user remains profoundly sedated for hours. This is the pharmacological basis for what street outreach workers call "the bend" or "tranq lean": users in a forward-folded posture, not quite unconscious, sometimes for many hours, vulnerable to robbery and sexual assault, and metabolizing the benzodiazepine slowly while their body weight presses on extremities.
Xylazine ("tranq"). Xylazine is a veterinary alpha-2 adrenergic agonist (not approved for human use) that depresses CNS, lowers heart rate and blood pressure, and — critically — causes peripheral vasoconstriction. It first appeared in Health Canada DAS samples in 2018 (5 samples); by 2023 there were over 1,300 detections, with the bulk from Ontario. The Toronto Drug Checking Service finds xylazine in roughly 10% of fentanyl samples; UVic's Vancouver Island data show about 3%. It is added because it lengthens and "smooths" the fentanyl high, partly compensating for fentanyl's short duration. Like benzodiazepines, xylazine does not respond to naloxone.
The combined effect. A 2024 fentanyl overdose in Hamilton may involve fentanyl (or fluorofentanyl, increasingly common), bromazolam, xylazine, and frequently methamphetamine or cocaine. Naloxone restores opioid respiratory drive but cannot reverse the xylazine-induced bradycardia and hypotension or the benzodiazepine-induced sedation. The post-naloxone period is therefore far longer and clinically messier than in the heroin era. This also helps explain a paradox in the 2024 Ontario data — opioid deaths are down about 15% from 2023 (to 2,231) while paramedic-witnessed events and visible street disability are up. Naloxone is preventing acute death but not the slow, semi-conscious, wound-accumulating decline.
4. The "Zombie" Appearance: What Is Actually Causing the Visible Decline
The dramatic deterioration visible on Hamilton streets is not a single phenomenon but the convergence of four pharmacologically and socially distinct processes:
Xylazine wounds
These are the open, weeping, often blackened ulcers — typically on legs, forearms, and hands — that have become emblematic of the "tranq" era. The mechanism is well-characterized in the dermatology and surgical literature (Malayala et al., Cureus 2022; Mukhopadhyay, JAAD 2023; Harm Reduction Journal 2024; Wu et al., Journal of Hand Surgery Global Online 2024; American College of Surgeons Bulletin, October 2025): xylazine is a peripheral alpha-2 (and partial alpha-1) adrenergic agonist that constricts cutaneous arterioles, sharply reducing skin perfusion. Local tissue ischemia plus repeated trauma at injection sites — and importantly, also at non-injection sites, since xylazine causes systemic vasoconstriction even when smoked or snorted — produces ulcers that fail to heal, become superinfected with Staph aureus, MRSA, Pseudomonas and anaerobes, and can extend into muscle and bone (osteomyelitis). Unlike methamphetamine "meth sores," which are caused by formication and compulsive scratching, xylazine wounds appear at sites the user never touched. Severe cases require surgical debridement and, increasingly, amputation. Surgeons have begun describing distinctive features: heavy eschar, surprisingly fast granulation if drug use is interrupted, but failure to graft if it is not.
This wound pattern essentially did not exist in Canadian street populations before about 2021. In Hamilton specifically, Health Canada DAS data show Ontario as the province with the highest xylazine detection nationally, and the appearance of these wounds among the visibly homeless population has accelerated through 2023–2026.
Benzodiazepine sedation and "the bend"
Bromazolam and its cousins produce the prolonged, forward-leaning, semi-conscious posture. Because they extend the "high" by 6–12 hours rather than fentanyl's 1–2, users effectively spend much more of their day immobile. Pressure injuries, frostbite (in winter), heat injuries (in summer), and aspiration pneumonia all increase. Users report frequent waking with no memory of the preceding hours, which complicates everything from medication adherence to documenting victimization.
Methamphetamine co-use
Methamphetamine has surged in the Canadian street supply alongside fentanyl. CCSA's Community Urinalysis and Self-Report Project tracks rising stimulant use. In Ontario in 2024, stimulants were detected in 69% of opioid toxicity deaths. People who combine fentanyl/benzo "down" with methamphetamine "up" cycle between profound sedation and amphetamine-driven wakefulness, often going days without sleep or food. The cumulative effect is the gaunt, agitated, prematurely-aged appearance — the loss of subcutaneous fat, the dental decay, the skin picking, the hyperreactivity — that is most of what people informally label "zombie." Stimulant psychosis adds paranoid behavior. This is a meaningfully different clinical picture than the heroin era, when users typically nodded into sedation, slept, ate, and could hold an outward appearance of relative health for years.
Homelessness, malnutrition, and untreated infection
The fourth ingredient is structural. Hamilton's actively homeless population has exceeded 1,500 since December 2021, a level driven by national housing-cost inflation and Ontario shelter shortages rather than by drugs per se. People living rough cannot keep wounds clean, cannot refrigerate medications, cannot complete antibiotic courses, lose access to identification and OHIP cards, and become essentially invisible to primary care. The interaction between xylazine wounds and rough sleeping is particularly vicious: a wound that might heal in a housed patient becomes chronic and limb-threatening in someone sleeping in a tent in February.
The honest comparison to the heroin era
A heroin user in 2005 was usually thin and chronically ill, but the visible street picture was different: nodding sedation, intact skin (apart from track marks and the occasional abscess), and longer life expectancy in active addiction. The current picture — dissociated catatonia, large necrotic wounds, methamphetamine-driven agitation, profound sleep deprivation, and rapid physical aging — is genuinely new and is worsening year over year as bromazolam and xylazine penetration increases. The user's perception that this has changed dramatically since roughly 2022–2023 is empirically correct.
5. Hamilton and Ontario: The Local Picture
Hamilton's specific situation
Hamilton's opioid death rate has run roughly 40–45% above the Ontario provincial average for years. The city declared opioid deaths an emergency in April 2023. Local data show 167 confirmed/probable opioid deaths in 2021 (peak), 166 in 2022, 150 in 2023, and 129 in 2024 — a real but modest decline that mirrors Ontario as a whole, attributable largely to naloxone saturation and a partial shift from injection to inhalation. Hamilton paramedics responded to 964 suspected opioid overdoses in 2023 (about 80/month) and 814 in 2022. The city's homeless population sits around 1,600.
The supervised consumption site closure and HART hubs
This is the single most important recent policy change for what the user is observing. Hamilton's only supervised consumption site (CTS), operated by the Hamilton Urban Core Community Health Centre at St. Paul's Presbyterian Church, was forced to close on March 31, 2025 under the Ford government's Safer Streets, Stronger Communities Act, 2024 (Bill 223), which banned consumption sites within 200 metres of schools or daycares. Nine of Ontario's 23 supervised consumption sites were forced to either close or transition into "Homelessness and Addiction Recovery Treatment" (HART) hubs by April 1, 2025. The HART hub model — funded at $378 million for 19 hubs, later expanded to $529 million for 27 hubs — explicitly prohibits needle exchange, drug checking, and supervised consumption, focusing instead on abstinence-based treatment, primary care, and supportive housing.
In June 2025, the province cut funding to seven additional sites in Toronto, Ottawa, Niagara, Peterborough, and London. In April 2026, funding for Ontario's last provincially supported supervised consumption site, in Kingston, was pulled. Ontario's auditor general found the original closures were "made without proper planning, impact analysis or public consultations." The legislation is currently subject to a Charter challenge by the Neighbourhood Group/Kensington Market site, and a temporary injunction has kept that one Toronto site open.
The empirical consequence in Hamilton
This is documented in Hamilton's own data. According to a motion before the Hamilton Board of Health in 2026, the average number of monthly opioid-related paramedic responses in Hamilton more than doubled in the eleven months following the CTS closure: from an average of 61 monthly calls (May 2024–March 2025) to an average of 134 monthly calls (May 2025–March 2026). Hamilton's medical officer of health, Dr. Elizabeth Richardson, stated in 2025 that "several weeks have recorded some of the highest weekly paramedic response counts in the last three years." The Hamilton Public Library considered temporarily closing its main branch because of overdoses inside the building. Comparable spikes were reported in Toronto, Ottawa, and Guelph.
The user's perception that downtown Hamilton has gotten dramatically worse since spring 2025 is consistent with this data. The drug-poisoned supply has not changed; what changed is that drug use has been pushed out of supervised indoor settings and into parks, alleys, libraries, and bus shelters.
Encampments and enforcement
Hamilton's city council reversed its 2023 encampment protocol on January 15, 2025, with full enforcement of the parks bylaw resuming March 6, 2025. Four bylaw officers were reassigned to enforcement. Federal housing advocate Marie-Josée Houle and the Canadian Civil Liberties Association both criticized the decision as inconsistent with Canada's human-rights obligations. The practical effect has been to push encampments around the city rather than dissolve them, while increasing the visibility of public drug use.
Ontario aggregate data
Ontario opioid deaths fell from 2,639 in 2023 to 2,231 in 2024 — a 15% drop, similar to declines seen across most of Canada and dwarfed by the U.S. drop of 27%. Fentanyl was involved in 83% of Ontario opioid toxicity deaths in 2024; benzodiazepines (prescription and non-prescription combined) in over 60%; cocaine in nearly 50%. Men account for 75% of deaths. About one in five opioid overdose deaths in Ontario occur in the homeless population. Ontario's chief coroner Dr. Dirk Huyer has explicitly said that the cause of the recent decline is uncertain — possibly a slightly less toxic supply, possibly naloxone saturation, possibly a shift to inhalation.
6. Policy Responses: What Is Being Tried
The harm reduction–enforcement debate
Canada's drug policy has whipsawed in the past five years between two paradigms:
The harm reduction model, dominant in BC and federal policy 2017–2024, holds that the toxic unregulated supply is the proximate killer; that prohibition increases toxicity (the "iron law of prohibition"); that the appropriate response is to reduce harm through naloxone, supervised consumption, drug checking, low-barrier opioid agonist therapy, and pharmaceutical-grade alternatives; and that decriminalization removes the stigma that keeps people from seeking care.
The recovery/enforcement model, dominant in Alberta since 2019 and Ontario since 2024, holds that harm reduction enables continued use; that the public-disorder externalities of decriminalization and consumption sites have become politically untenable; and that the proper response is abstinence-based treatment, expanded involuntary or compelled treatment, and tougher enforcement against trafficking.
Both paradigms can cite real evidence. Both have been politicized to the point that empirical questions are often answered by ideology.
Safer supply
"Safer supply" — typically prescribed hydromorphone tablets — peaked at about 4,946 BC patients in March 2023 and has since fallen to about 2,893 (October 2025). A controversial January 2025 study by Nguyen et al. in JAMA Health Forum found that BC's safer supply policy was associated with a 33% increase in opioid hospitalizations, and the addition of decriminalization with a 58% increase, but found no significant increase in opioid deaths. The authors offered competing interpretations: reduced stigma encouraging people to seek hospital care, or diversion of safer-supply hydromorphone to new opioid-naive users. The diversion narrative has been pushed hard by columnist Adam Zivo in the National Post and adopted by the Conservative Party of Canada. Counter-evidence from BC's own Ministry of Public Safety and Solicitor General — leaked in early 2025 — showed that hydromorphone accounted for just 0.3% of drugs seized by Vancouver Police by weight in 2023, suggesting diversion at scale is not occurring. The BC NDP government has nonetheless retreated, ending take-home doses for new patients in February 2025.
The BC decriminalization experiment
BC received a federal exemption under section 56(1) of the Controlled Drugs and Substances Act on January 31, 2023, allowing adults to possess up to 2.5g cumulatively of opioids, cocaine, methamphetamine, and MDMA. After roughly 15 months of intense political backlash over public drug use, BC asked Health Canada to amend the exemption in May 2024, restricting decriminalized possession to private residences, shelters, and harm-reduction sites. On January 14, 2026, Health Minister Josie Osborne announced BC would not renew the exemption when it expired January 31, 2026 — effectively ending the experiment. BC Coroners Service data show drug deaths in BC continued to rise after decriminalization, peaking at 2,589 in 2023 (an 8% increase), then falling 10% in 2024 after the rollback, and on track for roughly a 20% decline in 2025. A 2025 study in Drug and Alcohol Review found no statistically significant change in unregulated drug deaths attributable to the original exemption period itself.
Involuntary treatment
Alberta's Compassionate Intervention Act (2024–2025) authorizes involuntary treatment for severe substance use disorder. BC under Premier David Eby has expanded secure-care facilities for youth and proposed similar measures for adults with concurrent mental illness. These approaches are popular politically but face Charter challenges and weak evidence: a 2016 systematic review (Werb et al.) found involuntary treatment generally produced poorer outcomes than voluntary treatment, with several studies finding increased overdose risk on release because of lost tolerance.
The HART hub experiment
Ontario's HART hub model has been operating long enough (about a year as of early 2026) to assess. Canadian Affairs reported in March 2026 that staff describe positive outcomes but say demand vastly exceeds capacity, that several hubs (Ottawa, Guelph) opened with only partial services, that withdrawal-management beds and supportive-housing units have not been delivered at promised levels, and that the closure of supervised consumption services has displaced drug use into surrounding streets, alleys, and shelters. The Hamilton hub at Urban Core was expected to open a residential treatment program on Aberdeen Avenue in 2026. The Government of Ontario has pointed to a Canadian Centre of Recovery Excellence study of the Red Deer, Alberta closure that found no mortality increase, but the study's authors acknowledged it was inconclusive and limited to six months.
Naloxone
The most unambiguously successful intervention. The Public Health Agency of Canada's December 2025 analysis identified expanded naloxone distribution as the single most likely factor in the modest 2024 mortality decline, with regions distributing more kits experiencing larger drops in deaths.
Synthesis: How We Got Here
The Canadian fentanyl crisis is the cumulative product of decisions made and not made over thirty years. Health Canada's 1996 OxyContin approval, based on inadequate evidence and a misleading product monograph, opened the door. Purdue Pharma Canada walked through it with an aggressive marketing campaign that was never criminally prosecuted in Canada the way it was in the United States. By the mid-2000s, Canada was the world's second-highest opioid prescriber. The 2012 reformulation and provincial delistings cut the prescription supply without addressing the demand they had created, and a generation of opioid-dependent Canadians substituted toward heroin and then, very rapidly, toward illicit fentanyl arriving from China through BC ports and produced in Mexican labs from Chinese precursors.
The 2019 Chinese class-scheduling pushed finished-fentanyl shipments toward Mexican synthesis using Chinese (and increasingly Indian) precursors, and Canadian organized crime — particularly in BC — built domestic superlab capacity that now supplies parts of the international market. Trump-administration claims that Canada is a major source of U.S. fentanyl are not supported by seizure data, which show northern-border seizures at well under 1% of southern-border seizures. The "China weaponization" narrative is partially supported (PRC tolerance and tax-rebate subsidies of precursor exports are real and credibly documented) and partially overstated (a centrally-directed drug-war attack has not been substantiated by credible Canadian or U.S. national-security investigations, including the Hogue Commission).
What pushed the crisis from an opioid mortality problem into the visible street catastrophe Hamiltonians are now seeing was a pharmacological mutation around 2021–2023: bromazolam and other non-medical benzodiazepines mixed into fentanyl, xylazine added to extend the high, and methamphetamine increasingly used alongside. This combination produces prolonged sedation that naloxone cannot fully reverse, necrotic skin wounds that won't heal in someone sleeping rough, and a stimulant-driven agitation and emaciation that together produce the "zombie" appearance. It is genuinely different from the heroin or early-fentanyl era both pharmacologically and clinically.
Onto this pharmacological reality the Ford government has overlaid the closure of supervised consumption sites, the rollback of Hamilton's encampment protocol, and a transition to abstinence-based HART hubs whose treatment and housing capacity has not yet materialized at promised levels. Hamilton's own data show paramedic-attended opioid responses more than doubled in the eleven months after its CTS closed in March 2025. Drug use that was previously indoors, supervised, and occasionally fatal is now outdoors, unsupervised, and frequently visible in libraries, parks, and downtown sidewalks.
Ontario opioid deaths actually declined 15% from 2023 to 2024, in line with a broader North American trend driven by naloxone saturation, possibly a marginally less toxic supply, and a partial shift from injection to inhalation. But death counts are an incomplete metric: people are surviving overdoses that would have killed them in 2018 only to accumulate xylazine wounds, untreated infections, and benzodiazepine-related cognitive deterioration on the streets. The crisis is becoming less acutely lethal and more chronically grotesque. That is what is visible in Hamilton in 2026, and the available evidence suggests it will not improve substantially without simultaneous progress on housing, treatment access, supply toxicity, and the structural drivers — including the Chinese precursor trade — that academic researchers, the RCMP, the DEA, and even contested journalism agree are continuing largely unimpeded.
62 facts · 27 assertions → Pappin, Bavli, and Herder · OxyContin · Connecticut · Jason Busse · Insite · Vanda Felbab-Brown · U.S.-China Economic and Security Review Commission · DEA. Every one is a verbatim span; nothing was paraphrased into the graph.
This is a signed piece; its findings carry their sources inline, in the text. The piece argues; the sources carry the proof.